Latest news with #PrecisePRP
Business Upturn
30-07-2025
- Business
- Business Upturn
PetVivo Holdings Inc. to Trade on OTCQX Best Market
MINNEAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (OTCQX PETV; OTCID: PETVW) working in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively 'PetVivo' or the 'Company'), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for horses and companion animals, such as Spryng® with OsteoCushion® Technology and PrecisePRP®, today announced that the Company has qualified to trade on the OTCQX® Best Market. PetVivo Holdings Inc. upgraded to OTCQX from the OTCQB® Venture Market. PetVivo Holdings Inc. begins trading today on OTCQX under the symbol 'PETV.' U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on . The OTCQX Market is designed for established, investor-focused U.S. and international companies. The OTCQX Market has 625 securities as of today, while the broader OTC Markets Group includes approximately 12,000 securities. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors. PetVivo's signature product, SPRYNG with OsteoCushion Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal's subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis. PetVivo's other innovative product, PrecisePRP, is a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. PrecisePRP is a leucoreduced, allogeneic, pooled, freeze-dried PRP intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses. Unlike any PRP mechanical kits currently on the market, PrecisePRP™ does not require a blood draw or centrifugation making it a truly off-the-shelf product that is easy and convenient. Perhaps more important is the uniformity and consistency that PrecisePRP® guarantees. Each vial of PrecisePRP® contains a consistent dose of 4 billion platelets per vial at a concentration of 500,000 platelets per microliter and is leucoreduced with less than 1500 white blood cells per microliter. 'Qualifying to trade on the OTCQX Best Market is a significant milestone for our Company,' said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. 'This upgrade reflects our continued commitment to transparency, strong corporate governance, and delivering long-term value to our shareholders. Trading on OTCQX will enhance our visibility within the investment community and provide greater liquidity and accessibility for investors as we continue to execute on our strategic growth initiatives.' For more information about PetVivo Holdings, Inc. please contact [email protected] or visit , and . About PetVivo Holdings, Inc. PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for equine and companion animals. The Company's strategy is to leverage human therapies for the treatment of equine and companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics. PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protects the Company's biomaterials, products, production processes and methods of use. The Company's lead products SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale. CONTACT: John Lai, CEO PetVivo Holdings, Inc. Email: [email protected] (952) 405-6216
Yahoo
24-06-2025
- Business
- Yahoo
PETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF PURCHASE OPTION TIED TO SERIES B CONVERTIBLE PREFERRED STOCK OFFERING
MINNEAPOLIS, June 24, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) and its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively "PetVivo" or the 'Company') an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for horses, dogs and other companion animals announced today that the Company has recently received One Million Dollars ($1,000,000) pursuant to the full exercise of the remaining Shares offered in a purchase option ('Purchase Option') granted to the investor as part of an offering to receive Five Million Dollars ($5,000,000) of equity financing in exchange for Five Million shares of Series B Convertible Preferred Stock ('Shares') (the 'Offering'); pursuant to the Offering, the purchase price for one (1) Share of Series B Convertible Preferred Stock is One Dollar ($1.00) and the conversion rate is one (1) Share of Series B Convertible Preferred Stock for one (1) share of Company common stock. The Company has previously received an aggregate total of Four Million Dollars ($4,000,000) of the Offering prior to the current Purchase Option exercise. The exercise of the remaining One Million Dollars ($1,000,000) of the Purchase Option completes the issuance of all Shares allowed and thereby closes the Purchase Option of the Offering. The proceeds from this Offering are earmarked to assist the Company in the commercialization of its signature products, SPRYNG® with OsteoCushion® Technology and Precise PRP®. Spryng is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal's subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis. PrecisePRP is a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. PrecisePRP is a leucoreduced, allogeneic, pooled, freeze-dried PRP intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses. Unlike any PRP mechanical kits currently on the market, PrecisePRP™ does not require a blood draw or centrifugation making it a truly off-the-shelf product that is easy and convenient. Perhaps more important is the uniformity and consistency that PrecisePRP® guarantees. Each vial of PrecisePRP® contains a consistent dose of 4 billion platelets per vial at a concentration of Five Hundred Thousand (500,000) platelets per microliter and is leucoreduced with less than One Thousand Five Hundred (1500) white blood cells per microliter. 'We are pleased to announce the successful completion of the $5 million equity financing through the full exercise of the remaining shares under the Purchase Option. The additional $1 million investment reflects continued confidence by investors and our shareholders in our vision and growth strategy. This funding enables us to further accelerate the development and commercialization of our innovative portfolio of products, including Spryng and PrecisePRP, thereby enhancing our ability to deliver impactful solutions that improve the lives of animals and their caregivers.' For more information about PetVivo Holdings, Inc. please contact info1@ or visit and No Offer or Solicitation Nothing contained herein shall constitute an offer to sell or the solicitation of an offer to buy any security. The shares of Series B Convertible Preferred Stock ('Shares') were offered and sold to persons reasonably believed to be qualified accredited investors pursuant to Rule 144A under the Securities Act of 1933, as amended (the 'Securities Act'). The Shares have not been and will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. About PetVivo Holdings, Inc. PetVivo Holdings Inc. (OTCQB: PETV; OTCPINK: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics. PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company's lead products SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale. CONTACT: John Lai, CEO PetVivo Holdings, Inc. Email: info1@ (952) 405-6216 Forward-Looking Statements: The foregoing material may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as 'may,' 'will,' 'expect,' 'project,' 'estimate,' 'anticipate,' 'plan,' 'believe,' 'potential,' 'should,' 'continue' or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2024, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-06-2025
- Business
- Yahoo
PetVivo and Commonwealth Partner to Advance Equine Wellness Across Thoroughbred Racing
Minneapolis, MN, June 06, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), an emerging biomedical device company focused on animal health, today announced a strategic collaboration with Commonwealth, the syndicated ownership group behind 2023 Kentucky Derby winner Mage, and 2022 Dubai World Cup Champion Country Grammer. The partnership centers on the clinical use and promotion of SPRYNG® with OsteoCushion® Technology, PetVivo's cutting-edge intra-articular device designed to support joint health and durability, and Precise PRP™, a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians in elite equine athletes. As part of this collaboration, Commonwealth intends to integrate SPRYNG and PrecisePRP, when possible, into the care protocols of its top-tier thoroughbred stable, using the technology as both a preventative measure and a treatment solution to promote joint health, extend performance longevity, and support recovery in high-impact training and racing environments. In addition to clinical implementation, PetVivo and Commonwealth will explore co-branded content, educational initiatives, and industry outreach designed to elevate awareness around joint wellness and support broader adoption of SPRYNG and PrecisePRP across the equine health community. John Lai, CEO of PetVivo, commented, "Partnering with Commonwealth, a proven leader in the highest levels of the sport, marks a major milestone for SPRYNG and PrecisePRP. Their championship-caliber horses and progressive approach to wellness makes them the ideal partner to showcase the benefits of our technology. Together, we're advancing a shared vision of equine health that emphasizes performance, longevity, and science-backed care." Chase Chamberlin, CEO of Commonwealth, stated, 'At Commonwealth, our mission is to champion our equine athletes on and off the track. With HISA's new welfare protocols raising the bar for horse safety, SPRYNG and PrecisePRP are game‑changing advances in preventive and rehabilitative joint care. This partnership allows us to push the boundaries of equine medicine, while minimizing injury risk and downtime, so our horses can perform at their best. We're proud to join forces with PetVivo to deliver cutting‑edge treatments that safeguard the health and future of our champions.' Mike Eldred, Board Director at PetVivo, commented, 'We are excited to join forces with Commonwealth in advancing the clinical use of SPRYNG and Precise PRP. This partnership represents a significant step forward in our commitment to being the market leader in equine joint health and regenerative medicine. By combining PetVivo's clinical expertise and commercial capabilities, with Commonwealth's equine industry knowledge and network, we aim to provide veterinarians with cutting-edge, effective solutions that enhance recovery and long-term soundness in competitive horses.' About Commonwealth Commonwealth is a leading investment platform that allows fans to buy equity shares in thoroughbred racehorses starting at $50 per share. Dedicated to providing thrilling fan experiences that create lifelong memories and bring them closer than ever to the sport, Commonwealth campaigned 2023 Kentucky Derby winner Mage and the world's highest earning racehorse of 2022, Country Grammer. Learn more and download the app here. About PetVivo Holdings, Inc. PetVivo Holdings Inc. (OTCQB: PETV; OTCPINK: PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. PetVivo has a portfolio of twelve patents and six proprietary trade secrets that protect the company's biomaterials, products, production processes and methods of use. The company's lead products SPRYNG, is a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses. The company recently launched PrecisePRP, a first-in-class, off-the-shelf, allogenic, platelet-rich plasma (PRP) product. For more information about PetVivo Holdings, Inc. and our revolutionary products, Spryng and PrecisePRP, please contact info1@ or visit or Contact Information:John Lai, CEOPetVivo Holdings, info1@ 405-6216 Forward-Looking Statements: The foregoing material may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as 'may,' 'will,' 'expect,' 'project,' 'estimate,' 'anticipate,' 'plan,' 'believe,' 'potential,' 'should,' 'continue' or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to PetVivo and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the PetVivo's business are described in detail in PetVivo's Annual Report on Form 10-K for the year ended March 31, 2024, and other periodic and current reports filed with the Securities and Exchange Commission. PetVivo is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
